Skip to main content

Table 7 Univariate analysis with Log-rank test

From: Propensity score matching analysis of a phase II study on simultaneous modulated accelerated radiation therapy using helical tomotherapy for nasopharyngeal carcinomas

Factor

n

3-y LRRFS

3-y DMFS

3-y DFS

3-y OS

Events(n)

Survival

P*

Events(n)

Survival

P*

Events(n)

Survival

P*

Events(n)

Survival

P*

Age

  < 50

187

8

96.0%

0.127

9

94.9%

0.049

19

89.2%

0.002

14

91.6%

0.008

  ≥ 50

109

9

92.8%

 

12

90.9%

 

26

79.9%

 

20

82.8%

 

Gender

 Male

215

10

97.1%

0.207

19

93.9%

0.057

35

88.3%

0.397

27

88.0%

0.347

 Female

81

7

91.5%

 

2

97.0%

 

10

87.6%

 

7

89.2%

 

T Stage

 T1

88

2

98.9%

0.034

6

93.1%

0.855

9

88.6%

0.045

7

92.0%

0.321

 T2

89

3

96.4%

 

6

94.4%

 

10

89.8%

 

9

93.2%

 

 T3

68

8

86.2%

 

4

91.9%

 

13

79.8%

 

10

81.3%

 

 T4

51

4

90.3%

 

5

87.5%

 

13

71.6%

 

8

79.9%

 

Node category

 N-

43

2

95.0%

0.762

2

94.9%

0.537

4

90.1%

0.287

4

90.5%

0.664

 N+

253

15

97.2%

 

19

94.8%

 

41

82.9%

 

30

88.0%

 

N Stage

 N0

43

2

95.0%

0.625

2

94.9%

0.451

4

90.1%

0.401

4

90.5%

0.876

 N1

102

4

95.7%

 

7

92.1%

 

14

85.2%

 

11

90.0%

 

 N2

132

9

95.1%

 

12

91.1%

 

25

84.6%

 

17

87.1%

 

 N3

19

2

88.8%

 

0

100.0%

 

2

88.8%

 

2

86.1%

 

UICC Stage

 I

15

0

100.0%

0.125

0

100.0%

0.273

0

100.0%

0.019

0

100.0%

0.121

 II

76

1

98.6%

 

3

96.0%

 

5

93.3%

 

5

96.0%

 

 III

134

11

92.6%

 

13

90.3%

 

26

83.9%

 

20

84.4%

 

 IV

71

5

91.8%

 

5

90.9%

 

14

78.0%

 

9

84.4%

 

Induction chemotherapy was performed or not in stage III-IVpatients

 No

97

8

89.8%

0.608

9

88.8%

0.650

22

74.8%

0.172

18

79.9%

0.058

 Yes

108

8

91.5%

 

9

91.5%

 

18

82.6%

 

11

88.3%

 
  1. Abbreviation: 3-y LRRFS 3-year local-regional relapse free survival; 3-y DMFS 3-year distant metastasis free survival; 3-y DFS 3-year disease free survival; 3-y OS 3-year overall survival
  2. *P-values were calculated using the unadjusted log–rank test